Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary ...

Reviving lost species may help restore ecosystems, but it demands robust scientific oversight to ensure responsible use ...

The government aims to submit related legislation during next year's ordinary parliamentary session at the earliest.

Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...

After releasing two gene-edited rice varieties in May this year, scientists are now focusing on developing GE varieties of ...

Pseudoxanthoma elasticum (PXE) is an autosomal recessive connective tissue disorder caused by pathogenic variants in ATP-binding cassette subfamily C, member 6 (ABCC6). ABCC6 typically exports ATP, ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell ...

Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.

This agreement is subject to customary closing conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States.

Genetic engineering is moving from the lab bench into clinics, farms, and even family planning decisions, promising to change ...